Peptide API manufacturers by molecule

Vadodara drug maker, dating to 1907, with three API plants and six formulation plants. Holds US DMFs for 6 peptide APIs, including glatiramer and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

RK Pharma subsidiary offering API process R&D, custom synthesis and generic APIs, with US offices and plants in Gujarat and Andhra Pradesh. Holds US DMFs for 6 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Aspen Pharmacare's API site in Oss, Netherlands, with roots in 1923; makes peptides with a liquid-phase process plus hormones and heparin. Holds US DMFs for 4 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Tianjin unit of Asymchem, a CDMO listed in Shenzhen and Hong Kong that makes peptides and oligos; US DMFs for liraglutide and semaglutide.

Model

CDMO

Manufacturer?

Yes

Peptide API subsidiary of Aurobindo Pharma with a plant near Hyderabad. Makes generic peptide APIs and runs GMP contract projects from mg to kg scale.

Model

CDMO

Manufacturer?

Yes

Privately owned Barcelona peptide CDMO founded in 1989, making GMP generic peptide APIs and custom NCE peptides. Holds US DMFs for 10 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Bengaluru biopharma company that makes generic APIs and complex formulations, including GLP-1 peptides. Holds US DMFs for liraglutide, semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Changzhou API and tablet maker founded 1949 with a record of US FDA, EU GMP and PMDA inspections; US DMFs for semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Hangzhou peptide CRDMO founded in 2001, part of CPC Scientific/Medtide, with production in China and the USA. Holds US DMFs for cetrorelix, semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Taiwanese API maker founded in 1964, trading as Cenra API Solutions, offering CMO/CDMO services. Holds US DMFs for difelikefalin, plecanatide and setmelanotide.

Model

CDMO

Manufacturer?

Yes

Mumbai drugmaker founded in 1936 with six plants, including a US-FDA-accredited API site at Roha; holds an active US DMF for semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Hyderabad injectables CDMO founded 1978, promoted by Fosun Pharma; FDA-inspected sites; US DMF for glatiramer acetate.

Model

CDMO

Manufacturer?

Yes

Gwangju peptide API maker founded in 2000 as Anygen, KOSDAQ-listed since 2016, with MFDS-approved GMP peptide plants; holds US DMFs for ganirelix and vasopressin.

Model

CDMO

Manufacturer?

Yes

Riga drug maker operating since 1946 that now offers CDMO services; WHO-inspected oxytocin API site; US DMF for oxytocin.

Model

CDMO

Manufacturer?

Yes

Hyderabad-based MSN Group entity holding US DMFs for 11 peptide APIs, including semaglutide and tirzepatide. MSN runs 27 plants in India, the USA and Indonesia.

Model

CDMO

Manufacturer?

Yes

Indian CDMO whose Turbhe, Navi Mumbai site develops and makes peptide APIs by solid- and solution-phase synthesis. Holds US DMFs for 9 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Hamburg microbial biologics CDMO founded 1987, now wholly owned by Gedeon Richter; FDA-inspected 2013, 2018 and 2026; US DMF for teriparatide.

Model

CDMO

Manufacturer?

Yes

Raichur API and CDMO subsidiary of Shilpa Medicare; US DMFs for desmopressin, liraglutide and octreotide; Raichur units inspected by US FDA in 2025.

Model

CDMO

Manufacturer?

Yes

Neijiang, Sichuan injectables and API maker founded in 2010, listed on Shanghai's STAR Market, with FDA and UK MHRA GMP inspections; holds an active US DMF for lanreotide.

Model

CDMO

Manufacturer?

Yes

Jiangsu peptide CDMO and generic API supplier with large automated SPPS capacity; states it has passed four US FDA inspections. Holds US DMFs for 9 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Dutch holding entity of TAPI, Teva's API and CDMO business, with peptide development and GMP production across a global plant network. Holds US DMFs for 9 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Chinese maker of generic small-molecule, peptide and oligonucleotide APIs, founded in 1998, with an FDA-inspected site in Yangzhou. Holds US DMFs for semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

US peptide API CDMO with facilities in the US and China.

Model

CDMO

Manufacturer?

Yes

Swiss peptide and oligonucleotide CDMO with GMP plants in Europe and the US.

Model

CDMO

Manufacturer?

Yes

Greek peptide manufacturer producing GMP and non-GMP peptides and resins.

Model

CDMO

Manufacturer?

Yes

Chinese peptide drug manufacturer producing APIs and finished products.

Model

Manufacturer

Manufacturer?

Yes

Indian API manufacturer and CDMO with a peptide synthesis platform.

Model

CDMO

Manufacturer?

Yes

Peptide-focused CDMO running GMP manufacturing sites on three continents.

Model

CDMO

Manufacturer?

Yes

API manufacturer and CDMO focused on complex generics, including peptides.

Model

CDMO

Manufacturer?

Yes

Beijing API company, founded 2006, that holds DMFs and has its APIs made in partner facilities under its own quality control. Holds US DMFs for 13 peptide APIs.

Model

Manufacturer

Manufacturer?

Yes

US generics, specialty and biosimilars company with operations in the US, India and Ireland; US DMF for glatiramer acetate.

Model

Manufacturer

Manufacturer?

Yes

Nanjing API subsidiary of Nasdaq-listed Amphastar; US DMF for teriparatide.

Model

Manufacturer

Manufacturer?

Yes

Hyderabad API developer and maker founded in 2007, focused on niche and complex products. Holds US DMFs for cetrorelix, icatibant and sincalide.

Model

Manufacturer

Manufacturer?

Yes

California peptide synthesizer maker founded 1993 that also runs a cGMP peptide CDMO site in Milpitas; US DMF for triptorelin.

Model

CDMO

Manufacturer?

Yes

Italian API maker in the Italfarmaco Group, founded 1973, producing peptides since 1996; US DMFs for leuprolide and octreotide.

Model

Manufacturer

Manufacturer?

Yes

Chongqing maker of diabetes and obesity drugs, active since 2015 and controlled by Zhifei (300122) since 2025; US DMFs for liraglutide and semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Chongqing API maker founded in 2016 covering high-potency APIs, peptides and XDC compounds with CDMO services; reports FDA on-site inspections in 2024 and 2025 and holds a US DMF for semaglutide.

Model

CDMO

Manufacturer?

Yes

European CDMO network with a dedicated peptide, lipid and carbohydrate platform.

Model

CDMO

Manufacturer?

Yes

Fresenius Kabi's Italian API unit; its Villadose site near Venice develops and makes peptide APIs, also offered through Fresenius Kabi contract manufacturing. Holds US DMFs for 6 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Hangzhou recombinant drug maker listed in Hong Kong (02566), formerly Huadong Medicine's gene engineering centre; US DMF for liraglutide.

Model

Manufacturer

Manufacturer?

Yes

Hangzhou drug maker incorporated 1993, part of Shenzhen-listed Huadong Medicine; two group entities hold US DMFs for semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Mumbai peptide API maker acquired by Piramal Pharma in 2021; its oxytocin API is WHO-prequalified; US DMF for oxytocin.

Model

CDMO

Manufacturer?

Yes

Main operating subsidiary of Hong Kong-listed Hansoh Pharma, founded 1995; holds US DMFs for degarelix and icatibant.

Model

Manufacturer

Manufacturer?

Yes

Shenzhen peptide CDMO and API maker founded in 2009, with 13 cGMP lines and 85,000 L of SPPS/LPPS reactor volume. Holds US DMFs for 6 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Shenzhen-listed drug maker (002294) selling APIs and finished products; US DMF for bivalirudin.

Model

Manufacturer

Manufacturer?

Yes

Suzhou API and intermediate maker founded in 2000 offering CDMO/CMO services; holds an active US DMF for semaglutide.

Model

CDMO

Manufacturer?

Yes

Suzhou peptide API and formulation maker founded in 2000, flagship of Tianma Pharma Group, offering CRO/CMO/CDMO services. Holds US DMFs for 8 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Dubai-incorporated subsidiary of Zydus Lifesciences, the Ahmedabad drug group listed in India; US DMF for semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Beijing biotech founded in 2018 that develops and produces recombinant protein and peptide drugs in E. coli for metabolic disease; holds an active US DMF for semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Swiss Debiopharm plant in Martigny making triptorelin sustained-release products; US DMF for triptorelin pamoate microgranules.

Model

Manufacturer

Manufacturer?

Yes

Shanghai bulk peptide maker supplying wholesalers; holds US DMFs for bremelanotide, semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Putian, Fujian peptide API maker founded in 2019 by New Hope and Taiwan's Genovior, focused on GLP-1 APIs. Holds US DMFs for semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Zunyi, Guizhou peptide manufacturer offering development and kg-scale production; holds active US DMFs for tirzepatide and other peptides.

Model

CDMO

Manufacturer?

Yes

Hangzhou peptide and oligonucleotide CRDMO supporting projects from preclinical to commercial supply; holds active US DMFs for tirzepatide and inclisiran.

Model

CDMO

Manufacturer?

Yes

Hangzhou peptide maker founded in 2014 offering pharmaceutical, cosmetic and catalog peptides plus peptide CRO/CDMO work; holds an active US DMF for semaglutide.

Model

CDMO

Manufacturer?

Yes

Hangzhou peptide developer offering peptide APIs, intermediates, impurities and ADC/PDC linkers plus custom synthesis and process development; holds an active US DMF for tirzepatide.

Model

CDMO

Manufacturer?

Yes

Hangzhou peptide API maker and CDMO founded in 2019, supplying therapeutic and cosmetic peptides. Holds US DMFs for linaclotide, semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Privately held Hyderabad generics and API group with 36+ plants; US DMFs for semaglutide and vasopressin.

Model

Manufacturer

Manufacturer?

Yes

Changchun biopharmaceutical maker of somatropin, semaglutide and other APIs; holds active US DMFs for semaglutide and somatropin.

Model

Manufacturer

Manufacturer?

Yes

Nanjing supplier of insulin and metabolic peptide APIs with technology transfer services; US DMFs for semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Ningxia API and peptide maker founded in 2016 in Pingluo, offering peptide API development and manufacturing; holds US DMFs for semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Weihai Sino-US joint venture founded 2016 making peptide APIs and cosmetic peptides; US DMFs for leuprolide and semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Navi Mumbai biopharma and specialty pharma company; US DMFs for lanreotide and liraglutide.

Model

Manufacturer

Manufacturer?

Yes

Shenzhen peptide company founded in 2020 making GLP-1 peptide APIs, sterile vials and peptide reference materials at a Zhongshan plant; holds an active US DMF for tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Shenzhen synthetic-biology ingredient maker with semaglutide as its lead biopharma product; US DMFs for semaglutide main chain and side chain.

Model

Manufacturer

Manufacturer?

Yes

Leshan-based peptide producer founded in 2015 with SPPS and LPPS lines; holds US DMFs for eptifibatide, semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Suzhou peptide CRDMO with GMP workshops built to ICH Q7; US DMFs for semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Suzhou API and intermediates producer offering customized manufacturing. Holds US DMFs for semaglutide, thymalfasin and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Wuhan fermentation-based CDMO founded 2008 making GLP-1 APIs, proteases and cell products; US DMFs for semaglutide and its main chain.

Model

CDMO

Manufacturer?

Yes

Nantong company founded in 2020 that makes peptides by biosynthesis and offers peptide CMC development. Holds US DMFs for semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Hangzhou company founded in 2020 that makes GLP-1 peptides by fermentation plus semi-synthesis; holds an active US DMF for semaglutide API.

Model

Manufacturer

Manufacturer?

Yes

Mumbai drug maker incorporated in 1935 with plants in India and the USA. Holds US DMFs for difelikefalin, icatibant and terlipressin. Pithampur FDA warning letter still open.

Model

Manufacturer

Manufacturer?

Yes

Harbin peptide API maker founded in 2011. Holds US DMFs for 11 peptide APIs. FDA issued it a CGMP warning letter in May 2026 that remains open.

Model

Manufacturer

Manufacturer?

Yes

Nanjing maker of peptide, protein and polysaccharide APIs and finished products, registered in 2017. Holds US DMFs for semaglutide and tirzepatide. FDA warning letter issued Nov 2026.

Model

Manufacturer

Manufacturer?

Yes

Mumbai-based generics group that makes APIs and finished medicines. Holds US Type II DMFs for 15 peptide APIs, including GLP-1s and GnRH analogues.

Model

Manufacturer

Manufacturer?

Yes

Mumbai drug maker with its own API and formulation plants in India. Holds US DMFs for 3 peptide APIs. Received an FDA CGMP warning letter in November 2026.

Model

Manufacturer

Manufacturer?

Yes

Large Zhejiang API and generic drug maker founded in 1989 and listed in Shanghai; holds active US DMFs for semaglutide and a semaglutide intermediate. It has an open FDA warning letter from June 2025.

Model

Manufacturer

Manufacturer?

Yes